Canada Markets open in 21 mins

Mesoblast Limited (MESO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.77-0.28 (-4.63%)
At close: 04:00PM EST
5.55 -0.22 (-3.81%)
Pre-Market: 07:00AM EST

Mesoblast Limited

55 Collins Street
Level 38
Melbourne, VIC 3000
61 3 9639 6036

Full Time Employees102

Key Executives

NameTitlePayExercisedYear Born
Dr. Silviu ItescuFounder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director1.29MN/A1957
Mr. Josh Muntner BFA, M.B.A.Chief Financial Officer721.6kN/A1969
Mr. Peter T. Howard B.Sc., L.L.B., BSc, LLB (Hons)Gen. Counsel & Corp. Exec.N/AN/A1968
Mr. Michael Schuster M.B.A., MS, BSc, MBAHead of Pharma PartneringN/AN/A1977
Dr. Eric Strati M.B.A., Ph.D., Pharm.D., MBASr. VP of CommercialN/AN/AN/A
Dr. Fred GrossmanChief Medical OfficerN/AN/AN/A
Ms. Dagmar Rosa-Bjorkeson M.B.A., M.S.Chief Operating OfficerN/AN/A1964
Sir Jonathan Richard Symonds CBE, BA, FCAHead of Corp. Fin. & StrategyN/AN/A1959
Mr. Roger D. Brown BAHead of Spinal Orthopedic DisordersN/AN/AN/A
Dr. Paul J. Simmons BSc, Ph.D.Head of Research & New Product Devel.N/AN/A1959
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.

Corporate Governance

Mesoblast Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.